PD-1 inhibitors plus nab-paclitaxel-containing chemotherapy for advanced gallbladder cancer in a second-line setting: A retrospective analysis of a case series

Article Oncology

A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer

Bangyou Zuo et al.

Summary: Anti-PD-1 antibodies plus lenvatinib show effectiveness and tolerability in patients with advanced gallbladder cancer.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives

Davide Ciardiello et al.

Summary: Biliary tract cancers (BTC) are aggressive tumors with limited therapeutic options. Recent advances in understanding its molecular landscape have provided new possibilities for immunotherapy, but challenges remain. This review critically analyzes completed trials and discusses future directions and potential predictive biomarkers.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Meeting Abstract Oncology

A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1

Do-Youn Oh et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

A Phase II Study of Pembrolizumab in Combination with Capecitabine and Oxaliplatin with Molecular Profiling in Patients with Advanced Biliary Tract Carcinoma

Cecilia Monge et al.

Summary: This study demonstrates that the combination of capecitabine and oxaliplatin with pembrolizumab is well tolerated and potentially effective in treating refractory advanced biliary tract carcinoma. The study highlights the importance of a design framework for the precise characterization of individual tumors.

ONCOLOGIST (2022)

添加到收藏夹

Article Oncology

Combination chemotherapy with NAB(R)-paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL Pilot Study)

Rachel Woodford et al.

Summary: This study demonstrates the feasibility and potential efficacy of combination therapy with capecitabine and nab-paclitaxel as a second-line treatment for ABTC, warranting further assessment in formal phase II or III trials. The treatment was generally well tolerated, with encouraging disease control rates and survival outcomes.

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

The Efficacy and Safety of Sintilimab Combined With Nab-Paclitaxel as a Second-Line Treatment for Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Cancer

Jianzheng Wang et al.

Summary: Sintilimab combined with nab-paclitaxel as a second-line treatment for advanced gastric cancer/gastroesophageal junction cancer exhibits good anti-tumor activity and an acceptable safety profile, warranting further investigation and evaluation to identify more patients who can benefit from this combined treatment strategy.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study

Do-Youn Oh et al.

Summary: In patients with advanced biliary tract cancer, gemcitabine and cisplatin plus immunotherapy showed promising efficacy and acceptable safety, with an objective response rate of 66%. The most common adverse events were hematological, with no unexpected safety events observed.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

添加到收藏夹

Article Oncology

Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer A Multicenter Phase 2 Randomized Clinical Trial (GB-SELECT)

Anant Ramaswamy et al.

Summary: This study found that the use of CAPIRI regimen did not improve overall survival compared to irinotecan alone in patients with advanced gallbladder cancer who had received treatment with a gemcitabine-platinum regimen. More patients in the CAPIRI group required dose modification compared to those in the irinotecan group.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer

Qitong Zheng et al.

Summary: For patients with advanced gallbladder cancer, combination therapy using PD-1, targeted therapy, or chemotherapy is more effective than immunotherapy alone. The targeted therapy group shows early significant effects on disease control rate, while combination chemotherapy provides sustained effects.

ANNALS OF TRANSLATIONAL MEDICINE (2021)

添加到收藏夹

Review Oncology

Prolonged Response to HER2-Directed Therapy in Three Patients with HER2-Amplified Metastatic Carcinoma of the Biliary System: Case Study and Review of the Literature

Michael May et al.

Summary: HER2 amplification leading to receptor tyrosine kinase HER2 overexpression has been described in various malignancies. Targeted therapy has shown efficacy beyond breast and gastric cancers, including in biliary tract and ampullary carcinomas. Molecular analysis for HER2 amplification/overexpression should be considered in rare diseases with limited treatment options.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Programmed Death Ligand-1 (PD-L1) Is an Independent Negative Prognosticator in Western-World Gallbladder Cancer

Thomas Albrecht et al.

Summary: This study found that PD-L1 expression in Western-world GBC is heterogeneous and high tumoral PD-L1 expression predicts a negative prognosis, while the TIGIT/CD155 checkpoint may be a new target for GBC immunotherapy.

CANCERS (2021)

添加到收藏夹

Article Oncology

Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study

Milind Javle et al.

Summary: The study evaluated the activity of pertuzumab plus trastuzumab in patients with HER2-positive metastatic biliary tract cancer. The results showed a promising response rate and good tolerability, suggesting the need for further randomized, controlled trials in this patient population.

LANCET ONCOLOGY (2021)

添加到收藏夹

Article Oncology